An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Forte Biosciences, Inc.
VERDICT
The label
Markup
read at $76.86
Forte Biosciences Inc holds its Markup at $76.86.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-13
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 16 days
Price
$76.86
Valuation
N/A trailing · -19.48 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.65
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$76.86
N/A P/E · -19.48 fwd
Our fair value
$77.00
0% discount
Analyst target (avg)
$77.00
+0% to current
Target low $61.00Analyst target rangeTarget high $77.00
▲ current $76.86 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$76.86
you are here
Conservative
$61.00
-21%
Analyst avg
$77.00
+0%
Our fair value
$77.00
+0%
Analyst high
$77.00
+0%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our model and the Street both land near today's price — fairly valued, with no strong edge either way.
Profit margin
0.00%
Analyst consensus
Hold · 5 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its accounts receivable. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashCash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 94.0% of assets, above the 49% limit.Fail
Revenue purity of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Clinical stage biotech with no revenue or moat
Picture a lab racing to turn one antibody into a treatment for several autoimmune diseases, yet still years from any sales. Forte Biosciences sits in exactly that spot. The shares trade below our fair value estimate, analysts like the story, and the ethical screen raises no flags, yet the opportunity rating stays at none because the business has no moat, no profits, and negative returns on equity of 188 percent.
Forward earnings sit at a negative 11.8 times while the profit margin remains zero. The lead candidate, FB-102, targets CD122 but has yet to prove itself in large trials. Without recurring revenue or pricing power, any upside rests on binary clinical results rather than steady cash flow.
Risk sits around the usual biotech trap of repeated capital raises and trial setbacks that can wipe out value quickly. Even a clean ethical pass cannot offset the absence of a durable business. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in FBRX's space worth a look
Screened names in the same industry · explore each on its own page.
TRADER
The trader read · the latest dated commentary
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 178.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 24% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (4 analysts) rates it strong buy, with a mean price target of $64. Entered 2026-07-28 · Markdown
JOURNAL
The dated journal · newest first, never edited
2026-07-28Markdown$48.86+178.2%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 178.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 24% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (4 analysts) rates it strong buy, with a mean price target of $64.
2026-07-18Markdown$17.56+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 24% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (4 analysts) rates it strong buy, with a mean price target of $64.
2026-07-03Markdown$17.56+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$17.56Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$26.00
-35.5%
·
$645
-35.5%
2 months
$35.09
-52.2%
·
$478
-52.2%
3 months
$27.12
-38.2%
·
$618
-38.2%
6 months
$22.65
-26.0%
·
$740
-26.0%
1 year
$12.25
+36.9%
·
$1,369
+36.9%
2 years
$13.75
+22.0%
·
$1,220
+22.0%
3 years
$24.80
-32.4%
·
$676
-32.4%
5 years
$1,020.50
-98.4%
·
$16
-98.4%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever FBRX does next, these words stay.
Forte Biosciences Inc · FBRX · Markup · $76.86
Recorded 2026-08-13 · before the outcome · scored mechanically